- Home
- WIX vs EXAS Comparison
WIX vs EXAS Comparison
Compare WIX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIX
- EXAS
- Stock Information
- Founded
- WIX 2006
- EXAS 1995
- Country
- WIX Israel
- EXAS United States
- Employees
- WIX N/A
- EXAS N/A
- Industry
- WIX Computer Software: Programming Data Processing
- EXAS Medical Specialities
- Sector
- WIX Technology
- EXAS Health Care
- Exchange
- WIX Nasdaq
- EXAS Nasdaq
- Market Cap
- WIX 9.2B
- EXAS 10.7B
- IPO Year
- WIX 2013
- EXAS N/A
- Fundamental
- Price
- WIX $149.10
- EXAS $53.52
- Analyst Decision
- WIX Strong Buy
- EXAS Strong Buy
- Analyst Count
- WIX 18
- EXAS 20
- Target Price
- WIX $224.56
- EXAS $70.68
- AVG Volume (30 Days)
- WIX 1.2M
- EXAS 3.0M
- Earning Date
- WIX 08-06-2025
- EXAS 07-30-2025
- Dividend Yield
- WIX N/A
- EXAS N/A
- EPS Growth
- WIX 119.71
- EXAS N/A
- EPS
- WIX 2.51
- EXAS N/A
- Revenue
- WIX $1,814,525,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- WIX $13.94
- EXAS $14.58
- Revenue Next Year
- WIX $12.71
- EXAS $12.75
- P/E Ratio
- WIX $59.29
- EXAS N/A
- Revenue Growth
- WIX 12.89
- EXAS 11.57
- 52 Week Low
- WIX $137.94
- EXAS $39.97
- 52 Week High
- WIX $247.11
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- WIX 38.44
- EXAS 47.06
- Support Level
- WIX $150.47
- EXAS $53.61
- Resistance Level
- WIX $159.49
- EXAS $57.14
- Average True Range (ATR)
- WIX 4.40
- EXAS 1.68
- MACD
- WIX 0.08
- EXAS -0.62
- Stochastic Oscillator
- WIX 29.56
- EXAS 7.69
About WIX Wix.com Ltd.
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.